SUPERNUS PHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a)None.
(b)None.
(c)Insider Trading Arrangements and Policies.
The table below lists the insider trading arrangements adopted or terminated during the third quarter of 2026:
| Name and Title of Director or Officer | Rule 10b5-1 Trading Arrangement(1) | Trading Arrangement Adopted or Terminated | Date of Adoption or Termination | Duration of Trading Arrangement | Aggregate Number of Securities to be Purchased Pursuant to Trading Arrangement | Aggregate Number of Securities to be Sold Pursuant to Trading Arrangement |
|---|---|---|---|---|---|---|
| Jack KhattarPresident, Chief Executive Officer and Director | Yes | Terminated | August 12, 2026 | First Transaction Date through February 24, 2027 | — | 297,500 |
| Charles NewhallDirector | Yes | Terminated | August 12, 2026 | First Transaction Date through June 15, 2027 | — | 5,000 |
| William Todd HorichSenior Vice President, Chief Commercial Officer | Yes | Terminated | August 12, 2026 | First Transaction Date through March 12, 2027 | — | 44,000 |
(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.